Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CINRYZE · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| SC CINRYZE with rHuPH20 Dose Level 1 | EXPERIMENTAL | Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks |
| SC CINRYZE with rHuPH20 Dose Level 2 | EXPERIMENTAL | Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks |
| IV CINRYZE First, Then SC CINRYZE Dose 1 | EXPERIMENTAL | - |
| IV CINRYZE First, Then SC CINRYZE Dose 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CINRYZE with rHuPH20 | BIOLOGICAL | - |
| CINRYZE | BIOLOGICAL | C1 esterase inhibitor (human) |
Inclusion Criteria: To be eligible for this protocol, a subject must: 1. Provide informed consent/assent, as appropriate. 2. Have previously participated in CINRYZE Study 0624-200 and completed the subcutaneous therapy period in that study. 3. During the 3 consecutive months prior to screening, ha...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3 | PHASE3 | NTLA-2002, Normal Saline Administration |
| BioCryst Pharmaceuticals, Inc. | BCRX | 2 | PHASE3 | Berotralstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Donidalorsen |
| Pharvaris N.V. | PHVS | 1 | PHASE2 | deucrictibant |
| BioMarin Pharmaceutical Inc. | BMRN | 1 | PHASE1 | Dose 1 of BMN 331 |
| Astria Therapeutics, Inc. | ATXS | 1 | PHASE2 | STAR-0215 |
CINRYZE is used for the treatment and prevention of attacks of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. It is being studied in clinical trials for patients with HAE, including children under the age of 12.
CINRYZE is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is conducting clinical trials to evaluate the safety and efficacy of CINRYZE for hereditary angioedema.
CINRYZE is in Phase 2 clinical development. It is an investigational therapy for hereditary angioedema and has not yet been approved by regulatory authorities. Clinical trials are ongoing to assess its safety and effectiveness.
CINRYZE has been studied in several Phase 2 trials. These include NCT01095497, evaluating subcutaneous administration; NCT01095510, for children under 12; NCT01426763, testing subcutaneous delivery with recombinant human hyaluronidase; and NCT01756157, for prevention of angioedema attacks. All trials are completed.
Yes, CINRYZE is a monoclonal antibody. It is being developed as a treatment for hereditary angioedema, a condition marked by recurrent swelling episodes. Clinical trials have assessed its use in both adults and children.